N2OFF Rebrands to Nexentis, Focusing on Biotech Innovations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: Newsfilter
- Corporate Rebranding: On February 25, 2026, N2OFF announced its rebranding to Nexentis Technologies Inc. and a trading symbol change to NXTS, reflecting its transformation into a data-driven biotech company aimed at enhancing market competitiveness.
- Acquisition of MitoCareX: On October 20, 2025, N2OFF completed the acquisition of MitoCareX, a company focused on drug discovery for resistant cancers and inflammatory metabolic diseases, marking a strategic pivot from cleantech to biotechnology.
- Validation of MITOLINE™ Platform: MitoCareX has generated multiple rounds of in vitro data using its MITOLINE™ discovery engine, demonstrating anti-tumor activity and potential applications in inflammatory metabolic diseases, indicating a promising market outlook.
- Advancing Precision Oncology Pipeline: Nexentis is progressing a pipeline targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, aiming to translate its computational discoveries into development-ready assets, which is expected to drive long-term growth in the biotech sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
